Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced that Julian S.
Gangolli, President, North America, of GW Pharmaceuticals plc, has
been elected to Revance’s Board of Directors and will serve as a
member of the Audit Committee, effective July 1, 2016.
Mr. Gangolli brings over two decades of senior management
experience building and running operations and product
commercialization for leading biopharma firms. He was a member of
the executive management team that transformed Allergan into one of
the leading global specialty pharmaceutical companies.
“We are thrilled to add Julian Gangolli to our Board of
Directors. Julian has a distinguished track record successfully
overseeing product and brand strategy, commercialization campaigns
and business development activities in specialties such as
dermatology, neurology, and ophthalmology,” said Dan Browne,
President and Chief Executive Officer at Revance. “Julian had
direct involvement in the extraordinary growth of the botulinum
toxin market. He will be invaluable as we continue to progress
toward regulatory approval and commercialization of RT002
injectable, our novel neurotoxin product candidate, and further
expand our pipeline into a variety of therapeutic areas.”
“I am delighted to work with the Board and Revance’s executive
team to develop and commercialize the first truly novel botulinum
toxin platform in nearly three decades,” said Mr. Gangolli. “I
believe the company’s focus on new botulinum toxin formulations,
with truly differentiated properties to treat existing and new
indications, has the potential to position Revance to become a
market leader in neuromodulation. I look forward to being part of
the company’s success.”
Mr. Gangolli is President, North America of GW Pharmaceuticals,
spearheading the buildout of the company’s U.S. commercial
infrastructure in advance of the potential launch of its lead
therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in
late-stage development for diverse indications. Prior to joining GW
Pharma, Mr. Gangolli served as President of the North American
Pharmaceutical division of Allergan Inc. for 11 years, where he was
responsible for a 1,400 person integrated commercial operation with
sales exceeding $3.8 billion in 2014. Previously, he served as
Senior Vice President, U.S. Eye Care at Allergan, during which time
this division launched eight new products, helping to propel growth
at more than 20% a year over a 5‐year period. Prior to Allergan,
Mr. Gangolli served as Vice President, Sales and Marketing at
VIVUS, Inc., where he facilitated the successful transition of the
company from a research and development start-up into a niche
pharmaceutical company. Before VIVUS, Mr. Gangolli served in a
number of increasingly senior marketing roles at Syntex
Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the
UK. Mr. Gangolli received a BSc (Honors) degree in Applied
Chemistry and Business Studies from Kingston University in
England.
Concurrent with Mr. Gangolli’s appointment, James Glasheen,
Ph.D., will step down from the Revance Board of Directors. "Since
joining our board in 2004, Jim has been a valued advisor, seeing us
from our early development phase, through the initial public
offering and now into late-stage development of our neurotoxin,"
said Browne. “Through Technology Partners, Jim was an important
early investor in the company and is now making a natural
transition to other venture opportunities. We appreciate the
strategic guidance and financial acumen he brought to our Audit
Committee and boardroom and thank him for his many years of
contributions."
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology and
neurology. Revance’s trajectory to commercial success begins with
the company’s novel and proprietary TransMTS® carrier-peptide
delivery system applied to botulinum toxin. Revance is developing
daxibotulinumtoxinA, the company’s highly purified botulinum toxin,
for a broad spectrum of aesthetic and therapeutic indications,
including facial wrinkles and muscle movement disorders.
The company holds worldwide rights for all indications of
DaxibotulinumtoxinA Topical Gel (RT001), DaxibotulinumtoxinA for
Injection (RT002) and the TransMTS technology platform. Beyond
botulinum toxin, Revance believes the TransMTS technology can be
applied to transdermal, mid-dermal, or deep tissue delivery of a
variety of other macromolecules. More information on Revance can be
found at www.revance.com.
"Revance Therapeutics", TransMTS®, “Remarkable Science Changes
Everything”, and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to: statements about our business
strategy, our investigational drug product candidates, expected
efficacy of our drug product candidates, clinical development,
timeline and other goals and market for our anticipated products,
plans and prospects and statements about potential benefits of our
drug product candidates and our technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risk that clinical trials may
not have an effective design or generate positive results; our
ability to obtain and maintain regulatory approval of our drug
product candidates; our ability to obtain funding for our
operations; our plans to research, develop, and commercialize our
drug product candidates; our ability to achieve market acceptance
of our drug product candidates; unanticipated costs or delays in
research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the
size and growth potential of the markets for our drug product
candidates; our ability to successfully commercialize our drug
product candidates and the timing of commercialization activities;
the rate and degree of market acceptance of our drug product
candidates; our ability to develop sales and marketing
capabilities; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange
Commission (the "SEC"), including factors described in the
section entitled "Risk Factors" of our quarterly report on Form
10-Q filed on May 10, 2016. These forward-looking statements speak
only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160705005230/en/
Investors:Revance TherapeuticsJeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellanAmi Bavishi,
212-213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024